Entyce Appetite Stimulant for Dogs

ENTYCE provides a convenient, once-daily oral solution for treating inappetence. Please reference the chart for recommended dosages.

To administer ENTYCE, the bottle should be shaken gently and then the appropriate amount of solution withdrawn using the provided syringe. The syringe should be rinsed between treatment dose.¹

Weight of Dog		Dose
LBS	KG	ML
5	2.3	0.2
10	4.5	0.5
15	6.8	0.7
20	9.1	0.9
25	11.4	1.1
30	13.6	1.4
35	15.9	1.6
40	18.2	1.8
45	20.5	2.1
50	22.7	2.3
55	25.0	2.5
60	27.3	2.7
65	29.5	3.0
70	31.8	3.2
75	34.1	3.4
80	36.4	3.6
85	38.6	3.9
90	40.9	4.1

Field Study The clinical Field Study¹ demonstrated a significantly higher proportion of inappetent dogs that received ENTYCE® (carpromorelin oral solution) had increased appetite as comparerd to dogs that received placebo.

PRIMARY ENDPOINT: Owner Appetite Assessment

Success Rate on day 4

Parameter	Capromorelin	Placebo	P-Value
Treatment success-single-question assessment %*	68.6	44.6	0.0078
Treatment success-Owner Appetite Assessment, %†	56.2	26.8	0.0071
Percent change in body weight, mean (SD)	1.83(2.8)	0.11(3.61)	0.004
Percent change in Owner Appetite Assessment, mean (SD)	73.4(75.9)	35.6(53.9)	0.0125

*A dog was considered a treatment success if the owner answered that their dog's appetite was increased in response to the question,"Do you feel that during the study (over the 4± 1 days of treatment) your dog's appetite was increased, no change or decreased?"
†Treatment success was defined as an increase in total score? 5 from day 0 to day 3 ± 1 (scoring scale 5-25)

Study Design

Blinded, placebo-controlled, multi-site study

244 client-owned dogs enrolled, 2:1 randomization

Inappentence from a variety of causes

3 mg/kg once daily oral liquid for 4 days

All dogs enrolled in the study were evaluated for adverse reactions throughout the course of the study.

Adverse reactions reported in dogs administered ENTYCE oral solution compared with vehicle control.

Adverse Reactions*	ENTYCE (n=171)* n(%)	Placebo (n=73)* n(%)
Diarrhea	12 (7.0%)	5 (6.8%)
Vomiting	11 (6.4%)	4 (5.5%)
Elevated blood urea nitrogen (BUN)	7 (4.1%)	2 (2.7%)
Polydipsia	7 (4.1%)	1 (1.4%)
Elevated phosphorus	4 (2.3%)	1 (1.4%)
Hypersalivation	4 (2.3%)	0 (0.0%)
Abdominal discomfort	2 (1.2%)	0 (0.0%)
Flatulence	2 (1.2%)	0 (0.0%)
Lethargy/depression	2 (1.2%)	0 (0.0%)
Nausea	2 (1.2%)	0 (0.0%)
Elevated creatinine	1 (0.6%)	1 (1.4%)

*The following adverse reactions were reported in < 1% of dogs that were administered ENTYCe: hyperractivity, increased fecal volume, increased gut sounds and polyuria.

CONCLUSION This study demonstrates that a ghrelin receptor agonist, ENTYCE, can stimulate appetite and increase body weight in a large population of client-owned dogs with reduced appetite of varying etiologies and was well-tolerated.